ARCT News and Press, Arcturus Therapeutics Ltd. From 05/05/22

Three-month data from ARCT-154 booster trial show persistent neutralizing antibody activity against multiple variants of SARS-CoV-2 International pivotal Phase 3 booster trial preparations initiated with global CRO Arcturus Therapeutics Holdings Inc. (the “Com...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory ra...

Phase 3 pivotal study succeeds in endpoints using ARCT-154 for Covid-19; Emergency Use Authorization submitted to Vietnam with possible approval for use in coming weeks/months. Ability to expand ARCT-154 in the Covid-19 booster treatment market space; Company already received feedback...

Earnings news provided a crucial catalyst during Thursday's midday trading. American Airlines (NASDAQ:AAL) ranked among the standout performers, rising in the wake of its upbeat results. Meanwhile, Watsco (WSO) and Steel Dynamics (STLD) both rose after their respective quarterly updates. Look...

Gainers: Inozyme Pharma (INZY) +15%. Clarus Therapeutics (CRXT) +10%. MedAvail (MDVL) +5%. Syros Pharmaceuticals (SYRS) +5%. Magenta Therapeutics (MGTA) +4%. Losers: AlloVir (ALVR) -10%. Rite Aid (RAD) -9%. Windtree Therapeutics (WINT) -7...

Arcturus Therapeutics (NASDAQ:ARCT) was downgraded to Neutral at Citi with a price target of $29, down from $86, as the firm noted that the path forward for the company's mRNA vaccine ARCT-154 was 'too risky.' On April 20, the company reported data from an ongoing phase 1/2/3 trial ...

The shares of clinical-stage biotech, Arcturus Therapeutics (NASDAQ:ARCT), are trading lower in the morning hours Wednesday as Wall Street reacts to data for the company’s mRNA-based COVID-19 shot, ARCT-154. However, Piper Sandler chose to back the company and explained why the data sh...

Gainers: AlloVir (ALVR) +41%. Biophytis (BPTS) +22%. Clarus Therapeutics (CRXT) +22%. Healthcare Services (HCSG) +20%. BioSig Technologies (BSGM) +6%. Losers: Arcturus Therapeutics (ARCT) -22%. Diffusion Pharmaceuticals (DFFN) -13%. Seer (SEER) -7%. HTG Molecular...

Netflix (NFLX) -27% on Q1 earnings release & as it posts loss of 200,000 subscribers. Arcturus Therapeutics (ARCT) -14% announces 95% overall efficacy for mRNA-based COVID-19 shot. MedAvail Holdings (MDVL) -12%. SunLink Health Systems (SSY) -11%. Roku (ROKU) -7%. Sunsh...

Disclosing topline data from an ongoing Phase 1/2/3 clinical trial, RNA medicines company, Arcturus Therapeutics (NASDAQ:ARCT) said on Wednesday that its self-amplifying mRNA vaccine ARCT-154 showed 95% overall efficacy in the prevention of severe COVID-19 including related deaths. However, t...